LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
for Ulcerative Colitis (UC)
50 locations incl. Phoenix
Sponsor: Eli Lilly and Company
Sex: All·Age: 18 - 80
Code: NCT07415044·Phase 2·Recruiting·Listed Feb 2026
Medical University of South Carolina
Clinical research site in Charleston, South Carolina · 96 JONATHAN LUCAS ST, SUITE 309, CHARLESTON, SC 29425-8900 · (843) 792-3221 · Website
Part of Medical University of South Carolina
As of July 2026, 395 paid clinical trials are recruiting at Medical University of South Carolina in Charleston, South Carolina. Active studies at this site cover conditions such as Stroke, Depression and Parkinson Disease. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Recruiting clinical trials at Medical University of South Carolina (395)
Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)
for Hepatitis
48 locations incl. Birmingham
Sponsor: Bausch Health Americas, Inc.
Sex: All·Age: 18+
Code: NCT07428538·Phase 3·Recruiting·Listed Feb 2026
A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)
for Liver Cirrhosis
26 locations incl. Chandler
Sponsor: Boehringer Ingelheim
Sex: All·Age: 18 - 75
Code: NCT07325526·Phase 2·Recruiting·Listed Jan 2026
Parasternal Extravascular ICD System Pivotal Clinical Investigation (ALARION EV) Study
for Ventricular Arrythmia
27 locations incl. Scottsdale
Sponsor: AtaCor Medical, Inc.
Sex: All·Age: 18+
Code: NCT07324031·Recruiting·Listed Jan 2026
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
for Atopic Dermatitis
36 locations incl. Birmingham
Sponsor: Organon and Co
Sex: All·Age: 3 Months - 23 Months
Code: NCT07265479·Phase 3·Recruiting·Listed Dec 2025
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
for Ovarian Neoplasms
88 locations incl. Birmingham
Sponsor: Eli Lilly and Company
Sex: All·Age: 18+
Code: NCT07213804·Phase 3·Recruiting·Listed Oct 2025
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
for Breast Neoplasms
116 locations incl. Anchorage
Sponsor: Eli Lilly and Company
Sex: All·Age: 18+
Code: NCT07174336·Phase 3·Recruiting·Listed Sep 2025
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
for Elevated Lp(a)
127 locations incl. Gilbert
Sponsor: Eli Lilly and Company
Sex: All·Age: 18+
Code: NCT07157774·Phase 3·Recruiting·Listed Sep 2025
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
for Pulmonary Arterial Hypertension
15 locations incl. Scottsdale
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT07218029·Phase 3·Recruiting·Listed Oct 2025
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
for Cardiovascular Disease
201 locations incl. Alexander City
Sponsor: Amgen
Sex: All·Age: 50 - 105
Code: NCT07136012·Phase 3·Recruiting·Listed Aug 2025
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
for Metabolic Dysfunction Associated Steatohepatitis (MASH)
163 locations incl. Birmingham
Sponsor: Boehringer Ingelheim
Sex: All·Age: 18+
Code: NCT06632444·Phase 3·Recruiting·Listed Oct 2024
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
for Triple Negative Breast Cancer
124 locations incl. Birmingham
Sponsor: Gilead Sciences
Sex: All·Age: 18+
Code: NCT05633654·Phase 3·Recruiting·Listed Dec 2022
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
for Carcinoma, Non-Small-Cell Lung
129 locations incl. Daphne
Sponsor: Janssen Research & Development, LLC
Sex: All·Age: 18+
Code: NCT06667076·Phase 2·Recruiting·Listed Oct 2024
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
for Carcinoma, Non-Small-Cell Lung
86 locations incl. Huntsville
Sponsor: Eli Lilly and Company
Sex: All·Age: 18+
Code: NCT06890598·Phase 3·Recruiting·Listed Mar 2025
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
for Lymphoma, Large B-Cell, Diffuse
71 locations incl. Mobile
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT06890884·Phase 2·Recruiting·Listed Mar 2025
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
for Carcinoma, Non-Small-Cell Lung
88 locations incl. Huntsville
Sponsor: Eli Lilly and Company
Sex: All·Age: 18+
Code: NCT06119581·Phase 3·Recruiting·Listed Nov 2023
A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised
for COVID-19 Infection
65 locations incl. Canoga Park
Sponsor: Pfizer
Sex: All·Age: 18+
Code: NCT07013474·Phase 3·Recruiting·Listed Jun 2025
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
54 locations incl. Daphne
Sponsor: Hoffmann-La Roche
Sex: All·Age: 18+
Code: NCT06065748·Phase 3·Recruiting·Listed Oct 2023
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
for Diabetes Mellitus, Type 2
123 locations incl. Chandler
Sponsor: Cleerly, Inc.
Sex: All·Age: 55+·Accepts healthy volunteers
Code: NCT06112418·Recruiting·Listed Nov 2023
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
for Atopic Dermatitis
66 locations incl. Birmingham
Sponsor: AbbVie
Sex: All·Age: 18 - 63
Code: NCT06389136·Phase 3·Recruiting·Listed Apr 2024
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
for Hidradenitis Suppurativa
78 locations incl. Birmingham
Sponsor: AbbVie
Sex: All·Age: 12+
Code: NCT05889182·Phase 3·Recruiting·Listed Jun 2023
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
for NonSegmental Vitiligo
69 locations incl. Birmingham
Sponsor: Incyte Corporation
Sex: All·Age: 2 - 11
Code: NCT06548360·Phase 3·Recruiting·Listed Aug 2024
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
for Ovarian Cancer
38 locations incl. Mobile
Sponsor: Incyte Corporation
Sex: Female·Age: 18 - 99
Code: NCT07023627·Phase 2·Recruiting·Listed Jun 2025
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
for Non-Small Cell Lung Cancer
38 locations incl. Chandler
Sponsor: AbbVie
Sex: All·Age: 18+
Code: NCT06568939·Phase 2·Recruiting·Listed Aug 2024
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
for Multiple Myeloma
36 locations incl. Birmingham
Sponsor: AbbVie
Sex: All·Age: 18+
Code: NCT06158841·Phase 3·Recruiting·Listed Dec 2023
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
for Primary Biliary Cholangitis
51 locations incl. Birmingham
Sponsor: Gilead Sciences
Sex: All·Age: 18+
Code: NCT06051617·Phase 3·Recruiting·Listed Sep 2023
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
for Hypertension
70 locations incl. Scottsdale
Sponsor: Orchestra BioMed, Inc
Sex: All·Age: 18+
Code: NCT06059638·Recruiting·Listed Sep 2023
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
for Depressive Disorder, Major
43 locations incl. Tucson
Sponsor: Janssen Research & Development, LLC
Sex: All·Age: 18 - 74
Code: NCT06559306·Phase 3·Recruiting·Listed Aug 2024
A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
for Antineutrophil Cytoplasmic Antibody-associated Vasculitis
57 locations incl. Scottsdale
Sponsor: Amgen
Sex: All·Age: 18 - 100
Code: NCT06072482·Phase 4·Recruiting·Listed Oct 2023
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
for Parkinson Disease
45 locations incl. Sun City
Sponsor: Neuron23 Inc.
Sex: All·Age: 40 - 80
Code: NCT06680830·Phase 2·Recruiting·Listed Nov 2024
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
for Moderately to Severely Active Crohns Disease
92 locations incl. Dothan
Sponsor: Hoffmann-La Roche
Sex: All·Age: 16 - 80
Code: NCT06819878·Phase 3·Recruiting·Listed Feb 2025
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
for Solid Cancer
26 locations incl. Anchorage
Sponsor: Daiichi Sankyo
Sex: All·Age: 18+
Code: NCT06161025·Phase 2, Phase 3·Recruiting·Listed Dec 2023
Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body
for Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion
27 locations incl. Los Angeles
Sponsor: Bayer
Sex: All·Age: All ages
Code: NCT04142437·Recruiting·Listed Oct 2019
Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
for Cancer Weight Loss
25 locations incl. Tucson
Sponsor: Endevica Bio
Sex: All·Age: 18+
Code: NCT06937177·Phase 2·Recruiting·Listed Apr 2025
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
for Allergy
56 locations incl. Birmingham
Sponsor: DBV Technologies
Sex: All·Age: 1 - 3
Code: NCT07003919·Phase 3·Recruiting·Listed Jun 2025
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
for Areata Alopecia
41 locations incl. Birmingham
Sponsor: Eli Lilly and Company
Sex: All·Age: 6 - 17
Code: NCT05723198·Phase 3·Recruiting·Listed Feb 2023
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
for Progressive Pulmonary Fibrosis
74 locations incl. Birmingham
Sponsor: United Therapeutics
Sex: All·Age: 18+
Code: NCT05943535·Phase 3·Recruiting·Listed Jul 2023
A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care
for Eosinophilic Esophagitis (EoE)
29 locations incl. Phoenix
Sponsor: Regeneron Pharmaceuticals
Sex: All·Age: 1+
Code: NCT06693531·Recruiting·Listed Nov 2024
An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis
for Colitis, Ulcerative
27 locations incl. Mesa
Sponsor: Pfizer
Sex: All·Age: 18 - 64
Code: NCT06398626·Recruiting·Listed May 2024
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
for Amyloidosis
39 locations incl. La Jolla
Sponsor: Eidos Therapeutics, a BridgeBio company
Sex: All·Age: 18 - 75
Code: NCT06563895·Phase 3·Recruiting·Listed Aug 2024
Showing the 40 most relevant of 395 recruiting trials at this site. Browse all with filters →
More research sites in Charleston
- Medical University of South Carolina (MUSC) (29 trials)
- Ralph H. Johnson VA Medical Center, Charleston, SC (22 trials)
- Ralph H Johnson VA Medical Center (11 trials)
- MUSC (7 trials)
- Hollings Cancer Center (6 trials)
- MUSC Hollings Cancer Center (6 trials)
- Ralph H. Johnson VA Health Care System (6 trials)
- Medical University of South Carolina Hollings Cancer Center (5 trials)
- GSK Investigational Site (4 trials)
- Bon Secours Saint Francis Hospital (4 trials)
Explore more
Paid clinical trials in Charleston, SC · South Carolina clinical trials